VJOncology Podcast
by VJOncology
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 5 chart positions in 5 markets.
By chart position
- 🇸🇬SG · Medicine#1430K to 100K
- 🇨🇴CO · Medicine#643K to 10K
- 🇦🇪AE · Medicine#963K to 10K
- 🇭🇰HK · Medicine#117500 to 3K
- 🇵🇹PT · Medicine#186500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
19K to 63K🎙 ~2x weekly·216 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
37K to 126K🇸🇬79%🇨🇴8%🇦🇪8%+2 more - Active Followers
Loyal subscribers who consistently listen
11K to 38K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 17 epsHosts
Not detected.
Recent guests
Recent episodes
GU cancer highlights from ASCO 2026
Jul 17, 2026
16m 47s
Top updates from the ESMO Gastrointestinal Cancers Congress 2026
Jul 10, 2026
18m 55s
Highlights in lung cancer from ASCO 2026: LIBRETTO-432, CROWN, and more
Jun 26, 2026
16m 58s
Breast cancer highlights from ASCO 2026
Jun 19, 2026
17m 54s
Gastrointestinal cancer updates at ASCO 2026: RASolute 302, EMERALD-3, and more
Jun 12, 2026
16m 00s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/17/26 | genitourinary cancerASCO 2026+5 | Andrew ArmstrongSrikala Sridhar+2 | enfortumab vedotinpembrolizumab+10 | — | genitourinary cancerASCO 2026+7 | — | 16m 47s | ||
| 7/10/26 | gastrointestinal cancersKRAS G12D-targeted therapies+5 | Teresa MacarullaGiulia Martini+3 | Vall d’Hebron University HospitalUniversità degli Studi della Campania Luigi Vanvitelli+3 | Barcelona, SpainNaples, Italy+4 | ESMOgastrointestinal cancers+6 | — | 18m 55s | ||
| 6/26/26 | lung cancerASCO 2026+5 | Alessandro di FedericoErika Ruiz-Garcia+2 | LIBRETTO-432CROWN+9 | — | lung cancerASCO+6 | — | 16m 58s | ||
| 6/19/26 | breast cancerASCO 2026+4 | Oleg GluzJana de Boniface+2 | Evang. Krakenhaus “Bethesda” KlinikKarolinska Institutet+2 | Chicago, IL | breast cancerASCO+6 | — | 17m 54s | ||
| 6/12/26 | gastrointestinal cancerASCO 2026+3 | Ghassan Abou-AlfaYelena Janjigian+2 | EMERALD-3RASolute 302+6 | — | gastrointestinal cancerASCO 2026+4 | — | 16m 00s | ||
| 6/8/26 | oncologycancer research+5 | — | apalutamideADT+7 | Chicago | ASCO 2026cancer treatment+5 | — | 18m 40s | ||
| 5/15/26 | CAR T-cell therapysolid tumours+4 | — | CAR T-cell therapyarmoured CARs+2 | — | CAR T-cell therapysolid tumours+6 | — | 16m 57s | ||
| 5/8/26 | bladder cancerresearch advances+5 | Joaquim BellmuntEva Compérat+2 | Dana-Farber Cancer InstituteMedical University of Vienna+2 | Boston, MAVienna, Austria+2 | bladder cancerMRD monitoring+6 | — | 15m 41s | ||
| 5/1/26 | immuno-oncologytargeted therapy+4 | Bruno BockornyByoung Chul Cho+2 | PLN-101095denikitug+4 | Boston, MASeoul, South Korea+1 | AACR 2026immuno-oncology+7 | — | 17m 41s | ||
| 4/30/26 | advanced non-small cell lung cancerprecision oncology+4 | — | Jules Bordet InstitutePrincess Margaret Cancer Centre+2 | — | NSCLCtargeted agents+7 | — | 17m 11s | ||
| 4/17/26 | head and neck cancerclinical trials+4 | Kevin HarringtonTakeshi Kodaira+2 | The Institute of Cancer ResearchThe Royal Marsden NHS Foundation Trust+7 | London, UKNagoya, Japan+2 | head and neck cancerclinical trials+4 | — | 13m 35s | ||
| 3/27/26 | lung cancerscreening+5 | Robert RintoulLauren Dixon+2 | University of CambridgeLondon School of Hygiene & Tropical Medicine+3 | — | lung cancerscreening+5 | — | 18m 16s | ||
| 3/20/26 | cancer immunotherapytumor biology+5 | David GilesBernard Fox+1 | Washington University in St. Louis, MOProvidence Cancer Institute, Portland, OR+1 | — | immunotherapycancer+6 | — | 12m 52s | ||
| 3/6/26 | genitourinary cancersclinical trials+5 | Enrique Gallardo, MDJan-Jaap Mellema, MD+3 | Parc Taulí University HospitalNetherlands Cancer Institute+3 | Barcelona, SpainAmsterdam, The Netherlands+3 | ASCO GU 2026clinical trials+5 | — | 17m 50s | ||
| 2/20/26 | oesophageal cancergastroesophageal cancer+4 | Yelena Janjigian, MDBerend van der Wilk, MD+2 | Memorial Sloan Kettering Cancer CenterErasmus MC Cancer Institute+2 | — | oesophageal cancergastroesophageal cancer+4 | — | 17m 05s | ||
| 2/13/26 | circulating tumor DNAbreast cancer+5 | Wolfgang Janni, MDArielle Medford, MD+2 | University of UlmMassachusetts General Cancer Center+2 | Ulm, GermanyBoston, MA | ctDNAbreast cancer+6 | — | 16m 51s | ||
| 2/6/26 | checkpoint inhibitionimmunotherapy+4 | Jesus Fuentes-Antras, MDLaurence Buisseret, MD, PhD+1 | NEXT Oncology MadridInstitute Jules Bordet+1 | Madrid, SpainBrussels, Belgium+1 | checkpoint inhibitionPD-1+5 | — | 18m 41s |
Showing 17 of 17
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for VJOncology Podcast
Peaked at #14 in SG, currently #14 in SG.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SG | — | #14 | #14 | — |
| CO | — | #64 | #64 | — |
| SG | — | #92 | #92 | — |
| AE | — | #96 | #96 | — |
| HK | — | #117 | #117 | — |
| PT | — | #186 | #186 | — |
Chart Positions
6 placements across 5 markets.
Chart Positions
6 placements across 5 markets.